AU2011205290A1 — Use of an adrenal hormone-modifying agent

USPTO Abstract

The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or --C(O)N(R)(R) wherein R and R are independently --(C-C) alkyl, or --(C-C) alkyl-(C-C) aryl, wherein each of R and R is optionally substituted by --(C-C) alkoxy; R, R, and R, are independently hydrogen, halogen, cyano or --(C-C) aryl, wherein said --(C-C) aryl is optionally substituted by halogen, with the proviso that no more than one of R, R, and R is hydrogen; and R and R are hydrogen; or a pharmaceutically acceptable salt thereof.